Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amylyx Pharmaceuticals Inc AMLX

Healthcare
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company... see more

Recent & Breaking News (NDAQ:AMLX)

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 14, 2024

The Law Offices of Frank R. Cruz Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of Investors

Business Wire February 14, 2024

Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data - Hagens Berman

Newsfile February 14, 2024

Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Accesswire February 14, 2024

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire February 14, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Pharmaceuticals, Inc. Lawsuit - AMLX

Accesswire February 14, 2024

AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX

Business Wire February 14, 2024

Shareholders that lost money on Amylyx Pharmaceuticals, Inc.(AMLX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

Accesswire February 14, 2024

AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors Can Join the Class Action Lawsuit!

Accesswire February 14, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit - AMLX

Accesswire February 13, 2024

Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations

Business Wire February 13, 2024

Lost Money on Amylyx Pharmaceuticals, Inc.(AMLX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire February 13, 2024

Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire February 13, 2024

Amylyx Pharmaceuticals (AMLX) Sued For Securities Fraud After Analyst Questions RELYVRIO Data - Hagens Berman

Accesswire February 13, 2024

Amylyx Ongoing Deadline Alert

Newsfile February 13, 2024

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire February 13, 2024

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Investors

Business Wire February 13, 2024

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile February 13, 2024

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMLX

Newsfile February 13, 2024

Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Newsfile February 13, 2024